企业档案
会员类型：标准版
已获得阿仪网信誉 等级评定
(0 -40)基础信誉积累，可浏览访问
(41-90)良好信誉积累，可接洽商谈
(91+ )优质信誉积累，可持续信赖
阿仪网标准版会员：8年
工商认证 【已认证】
最后认证时间：无需年检
注册号：**** 【已认证】
法人代表：谭春** 【已认证】
参观次数：2676310
技术文章
文献引用产品：人脐静脉内皮细胞HUVECs
点击次数：597 发布时间：2026/6/18 13:22:41
文章标题：Paris saponin VII suppresses osteosarcoma progression by targeting VEGFR2 and PD-L1 to enhance anti-angiogenic and immunotherapeutic efficacy
作者列表：Ma Zuyi, Sun Jia, Wu Xin, Shang Changzhen, Li Binglu
影响因子：6
期刊：Cancer Cell International
发表时间：2026-4-6
DOI:10.1186/s12935-026-04289-0
文献主题：Abstract
Objective
To investigate the inhibitory effects and underlying mechanisms of Paris saponin VII (PS VII) on osteosarcoma (OS) progression.
Methods
Human osteosarcoma MG63 cells were treated with PS VII at concentrations of 0, 1, and 10 µmol·L⁻¹. Cell viability was assessed using the Cell Counting Kit-8 (CCK-8) assay, and clonogenic capacity was evaluated by colony ｆormation assays. Potential molecular targets of PS VII were predicted using the SwissTargetPrediction database. Intersection targets between PS VII-related targets and OS differentially expressed genes (DEGs) were identified, followed by protein–protein interaction (PPI) network construction to screen core targets. Molecular docking was perｆormed to validate compound–target interactions. Western blotting was used to verify the regulatory effects of PS VII on key protein targets. In vivo, a K7M2 murine osteosarcoma subcutaneous xenograft model was established to evaluate tumor growth and therapeutic synergy with bevacizumab or anti-PD-1 antibody.
原创作者：上海雅吉生物科技有限公司
